A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) multicenter trial II

X Schiel; H Link; G Maschmeyer; B Glass; OA Cornely; D Buchheidt; Martin Wilhelm; G Silling; M Helmerking; W Hiddemann; H Osterman; M Hentrich

doi:10.1007/s15010-006-5113-9

A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) multicenter trial II

X Schiel, H Link, G Maschmeyer, B Glass, OA Cornely, D Buchheidt, Martin Wilhelm, G Silling, M Helmerking, W Hiddemann, H Osterman, M Hentrich

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Original Article › peer-review

29 Citations (Web of Science)

Original language	English
Pages (from-to)	118-126
Journal	INFECTION
Volume	34
Issue number	3
DOIs	https://doi.org/10.1007/s15010-006-5113-9
Publication status	Published - 2006

Keywords

LIPOSOMAL AMPHOTERICIN-B
CEFTAZIDIME PLUS AMIKACIN
PERSISTENT FEVER
ANTIMICROBIAL AGENTS
IMMUNOCOMPROMISED PATIENTS
GRANULOCYTOPENIC PATIENTS
COMBINATION THERAPY
FUNGAL-INFECTIONS
UNEXPLAINED FEVER
2002 GUIDELINES

Access to Document

10.1007/s15010-006-5113-9

Cite this

Schiel, X., Link, H., Maschmeyer, G., Glass, B., Cornely, OA., Buchheidt, D., Wilhelm, M., Silling, G., Helmerking, M., Hiddemann, W., Osterman, H., & Hentrich, M. (2006). A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) multicenter trial II. INFECTION , 34(3), 118-126. https://doi.org/10.1007/s15010-006-5113-9

Schiel, X ; Link, H ; Maschmeyer, G et al. / A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) multicenter trial II. In: INFECTION 2006 ; Vol. 34, No. 3. pp. 118-126.

@article{af5d470e17bf4881b6c95fa3381c898d,

title = "A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) multicenter trial II",

keywords = "LIPOSOMAL AMPHOTERICIN-B, CEFTAZIDIME PLUS AMIKACIN, PERSISTENT FEVER, ANTIMICROBIAL AGENTS, IMMUNOCOMPROMISED PATIENTS, GRANULOCYTOPENIC PATIENTS, COMBINATION THERAPY, FUNGAL-INFECTIONS, UNEXPLAINED FEVER, 2002 GUIDELINES",

author = "X Schiel and H Link and G Maschmeyer and B Glass and OA Cornely and D Buchheidt and Martin Wilhelm and G Silling and M Helmerking and W Hiddemann and H Osterman and M Hentrich",

year = "2006",

doi = "10.1007/s15010-006-5113-9",

language = "English",

volume = "34",

pages = "118--126",

journal = "INFECTION ",

issn = "0300-8126",

number = "3",

}

Schiel, X, Link, H, Maschmeyer, G, Glass, B, Cornely, OA, Buchheidt, D, Wilhelm, M, Silling, G, Helmerking, M, Hiddemann, W, Osterman, H & Hentrich, M 2006, 'A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) multicenter trial II', INFECTION , vol. 34, no. 3, pp. 118-126. https://doi.org/10.1007/s15010-006-5113-9

A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) multicenter trial II. / Schiel, X; Link, H; Maschmeyer, G et al.
In: INFECTION , Vol. 34, No. 3, 2006, p. 118-126.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) multicenter trial II

AU - Schiel, X

AU - Link, H

AU - Maschmeyer, G

AU - Glass, B

AU - Cornely, OA

AU - Buchheidt, D

AU - Wilhelm, Martin

AU - Silling, G

AU - Helmerking, M

AU - Hiddemann, W

AU - Osterman, H

AU - Hentrich, M

PY - 2006

Y1 - 2006

KW - LIPOSOMAL AMPHOTERICIN-B

KW - CEFTAZIDIME PLUS AMIKACIN

KW - PERSISTENT FEVER

KW - ANTIMICROBIAL AGENTS

KW - IMMUNOCOMPROMISED PATIENTS

KW - GRANULOCYTOPENIC PATIENTS

KW - COMBINATION THERAPY

KW - FUNGAL-INFECTIONS

KW - UNEXPLAINED FEVER

KW - 2002 GUIDELINES

U2 - 10.1007/s15010-006-5113-9

DO - 10.1007/s15010-006-5113-9

M3 - Original Article

C2 - 16804654

SN - 0300-8126

VL - 34

SP - 118

EP - 126

JO - INFECTION

JF - INFECTION

IS - 3

ER -

Schiel X, Link H, Maschmeyer G, Glass B, Cornely OA, Buchheidt D et al. A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) multicenter trial II. INFECTION . 2006;34(3):118-126. doi: 10.1007/s15010-006-5113-9